TSLP Human, His
Description
Product Specs
Product Science Overview
Thymic Stromal Lymphopoietin (TSLP) is a hemopoietic cytokine that plays a crucial role in the immune system. It signals through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor (TSLPR) and the Interleukin-7 receptor alpha chain (IL-7Rα). TSLP is primarily expressed in the heart, liver, and prostate, and it is involved in the regulation of immune responses, particularly in allergic inflammation .
The human recombinant TSLP with a His tag is typically produced in Escherichia coli (E. coli). The recombinant protein is a single, non-glycosylated polypeptide chain containing 141 amino acids, including a 10 amino acid His tag at the N-terminus. The total calculated molecular mass is approximately 16.2 kDa . The protein is filtered and lyophilized in phosphate-buffered saline for storage and use .
TSLP impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes. It also promotes the growth of CD11c(+) dendritic cells. TSLP-activated dendritic cells prime naive T cells to produce pro-allergic cytokines such as Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-13 (IL-13), and TNF-alpha, while down-regulating Interleukin-10 (IL-10) and IFN-gamma .
TSLP functions as an alarmin and growth factor in the immune system. It is involved in type 2 immune responses (TH2 responses) and the maturation and recruitment of dendritic cells, T cells, B cells, neutrophils, mast cells, and other lymphoid cells. TSLP can be produced by epithelial and stromal cells in the lung, skin, and gastric system, as well as by dendritic cells, basophils, and mast cells . Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and mechanical injury .
TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies. It induces the expression of OX40L, CD80, and CD86, and stimulates CD4+ T cells . In 2021, the TSLP-neutralizing antibody tezepelumab was approved for the treatment of severe asthma . Targeting TSLP is an active area of investigation, with ongoing clinical trials for the treatment of autoimmune disorders .
